Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • aripiprazole

    - PMLiVE

    BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation

    The report shows how prehabilitation can improve patient experience while alleviating capacity pressures

    - PMLiVE

    BMS acquires Orbital Therapeutics in $1.5bn deal

    The deal includes several next-gen cell therapy candidates for autoimmune diseases

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    - PMLiVE

    BMS granted FDA approval for immunotherapy combination in colorectal cancer

    More than 154,000 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

    Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

    - PMLiVE

    BMS granted EC approval for immunotherapy combination in liver cancer

    More than 866,100 cases of the disease were diagnosed globally in 2022

    - PMLiVE

    Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

    Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

    - PMLiVE

    BMS receives CHMP recommendation for Breyanzi in follicular lymphoma

    The disease is the second most common form of non-Hodgkin lymphoma, accounting for up to 30% of cases

    - PMLiVE

    BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

    Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

    - PMLiVE

    BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial

    Over 154,000 cases of colorectal cancer are expected to be diagnosed in the US in 2025

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links